Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: April 29, 2010
Last updated: July 5, 2016
Last verified: July 2016